🇺🇸 FDA
Patent

US 10342791

Regimens of tafenoquine for prevention of malaria in malaria-naive subjects

granted A61KA61K31/4706A61P

Quick answer

US patent 10342791 (Regimens of tafenoquine for prevention of malaria in malaria-naive subjects) held by The United States of America as represented by the Secretary of the Army expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Secretary of the Army
Grant date
Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61K, A61K31/4706, A61P, A61P33/06